Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 42, 3315s-3321s, August 1, 1982]
© 1982 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Salhanick, H. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Salhanick, H. A.

Basic Studies on Aminoglutethimide1

Hilton A. Salhanick

Department of Population Sciences, Harvard School of Public Health, and Department of Obstetrics and Gynecology, Harvard Medical School, Boston, Massachusetts 02115

Aminoglutethimide (AG), a bicyclic substance with two optically active isomers, inhibits the cholesterol side-chain cleavage (SCC) and aromatase systems by blocking the terminal cytochrome P-450s. AG interacts with these cytochromes to induce typical type II, low-spin spectra; the amount of spectral change correlates directly with the amount of enzymatic inhibition. AG acts by preventing reduction of the cytochrome, an obligate step preceding oxygenation of substrate. The apparent Ki of D(+)-AG is about 2.5 times less than the Ki of L(–)-AG in inhibiting SCC and about 40 times less in inhibiting aromatase. The spectral Ks ratios of the D- and L-enantiomers for P-450SCC and P-450aromatase are 2.5 and 5, respectively, in the presence of substrate. The slope of the substrate concentration versus inhibition curves is less than 0.1 and extends over 2 logarithmic units of substrate concentration.

By in vivo rabbit and rat assays for SCC, D-AG is 5 and 25 times more potent than L-AG. In women, AG rapidly lowers estrogen and progesterone levels in the luteal phase of the menstrual cycle and in early pregnancy, eliciting a reflex release of luteinizing hormone in the luteal phase. In postmenopausal, adrenalectomized, ovariectomized women, AG prevents the aromatization of administered androstenedione.

In inhibition studies in women, plasma steroid concentrations were inversely proportional to AG levels, which were about 20 to 30 µM. This level of AG, which approximates the apparent Kis of the SCC and aromatase systems, caues a decrease in hormone levels of about 50%.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1982 by the American Association for Cancer Research.